Reshaping the HIV treatment and prevention landscape
Shingrix
Aim to double revenues in the next five years, protecting more than 100m adults
Major opportunity in US, China and beyond
Expanding target populations: 50+ & 18+
(immunocompromised)
~1.9bn 50+ people worldwide +
~ 90m new people each year1
US opportunity ~100m 50+ people remain
unvaccinated with Shingrix2
Untapped China
opportunity
gsk
Gold standard for shingles prevention
Unprecedented high efficacy >90% with proven 4-year
duration of protection³
- Unconstrained supply to support growth ambition
-
-
Geographic expansion: 35 markets
within next 3 years
Active life cycle management
-
– Label expansion: e.g., auto-immune disease
- Fully liquid formulation
SHINGRIX
回
HERPES ZOSTER VACCINE (NON-LIVE
RECOMBINANT, AS01, ADJUVANTED)
1. United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019, custom data acquired via website 2. 121m 50+ people in US in 2021 based on ACIP recos. 24m
vaccinated with Shingrix between 2017 and 2020 which leaves 97m yet to get vaccinated. 3. >80%, proven 8-year duration of protection https://academic.oup.com/ofid/article/7/Supplement 1/S4/6057510)
Shingrix, ambition uses 2020 base.
19
64View entire presentation